image
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 21.17
-1.76 %
$ 1.14 B
Market Cap
-8.3
P/E
1. INTRINSIC VALUE

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software.[ Read More ]

The intrinsic value of one CDNA stock under the base case scenario is HIDDEN Compared to the current market price of 21.2 USD, CareDx, Inc is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CDNA

image
FINANCIALS
280 M REVENUE
-12.89%
-102 M OPERATING INCOME
-31.94%
-190 M NET INCOME
-148.37%
-18.4 M OPERATING CASH FLOW
27.14%
40.4 M INVESTING CASH FLOW
117.70%
-29.6 M FINANCING CASH FLOW
-552.83%
82.9 M REVENUE
-10.18%
-10.5 M OPERATING INCOME
-160.35%
-7.41 M NET INCOME
-431.42%
12.5 M OPERATING CASH FLOW
-33.92%
-14.4 M INVESTING CASH FLOW
-23.91%
1.42 M FINANCING CASH FLOW
129.32%
Balance Sheet Decomposition CareDx, Inc
image
Current Assets 314 M
Cash & Short-Term Investments 235 M
Receivables 51.1 M
Other Current Assets 27.2 M
Non-Current Assets 171 M
Long-Term Investments 586 K
PP&E 65.1 M
Other Non-Current Assets 105 M
Current Liabilities 78.1 M
Accounts Payable 12.9 M
Short-Term Debt 5.94 M
Other Current Liabilities 59.3 M
Non-Current Liabilities 127 M
Long-Term Debt 28.3 M
Other Non-Current Liabilities 99.1 M
EFFICIENCY
Earnings Waterfall CareDx, Inc
image
Revenue 280 M
Cost Of Revenue 102 M
Gross Profit 178 M
Operating Expenses 278 M
Operating Income -102 M
Other Expenses 88.4 M
Net Income -190 M
RATIOS
63.61% GROSS MARGIN
63.61%
-36.35% OPERATING MARGIN
-36.35%
-67.88% NET MARGIN
-67.88%
-72.81% ROE
-72.81%
-40.76% ROA
-40.76%
-39.02% ROIC
-39.02%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis CareDx, Inc
image
Net Income -190 M
Depreciation & Amortization 19.8 M
Capital Expenditures -9.24 M
Stock-Based Compensation 49.1 M
Change in Working Capital 106 M
Others 83.4 M
Free Cash Flow -27.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets CareDx, Inc
image
Wall Street analysts predict an average 1-year price target for CDNA of $32.4 , with forecasts ranging from a low of $15 to a high of $40 .
CDNA Lowest Price Target Wall Street Target
15 USD -29.15%
CDNA Average Price Target Wall Street Target
32.4 USD 53.05%
CDNA Highest Price Target Wall Street Target
40 USD 88.95%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership CareDx, Inc
image
Sold
0-3 MONTHS
4.33 M USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 months ago
Aug 20, 2024
Sell 1.31 M USD
Johnson Alexander L
See Remarks
- 39466
33.17 USD
2 months ago
Aug 21, 2024
Sell 702 K USD
Johnson Alexander L
See Remarks
- 21557
32.58 USD
2 months ago
Aug 20, 2024
Sell 294 K USD
Maag Peter
Director
- 8844
33.23 USD
2 months ago
Aug 20, 2024
Sell 462 K USD
Maag Peter
Director
- 13890
33.25 USD
2 months ago
Aug 20, 2024
Sell 419 K USD
Maag Peter
Director
- 12818
32.67 USD
2 months ago
Aug 19, 2024
Sell 268 K USD
Johnson Alexander L
See Remarks
- 8000
33.53 USD
2 months ago
Aug 19, 2024
Sell 90.8 K USD
Johnson Alexander L
See Remarks
- 2683
33.83 USD
2 months ago
Aug 19, 2024
Sell 789 K USD
Johnson Alexander L
See Remarks
- 23548
33.52 USD
1 year ago
Oct 02, 2023
Sell 19.5 K USD
Seeto Reginald
See Remarks
- 2818
6.9139 USD
1 year ago
Sep 05, 2023
Sell 26.8 K USD
Seeto Reginald
See Remarks
- 2819
9.4935 USD
1 year ago
Aug 14, 2023
Sell 5.12 K USD
Seeto Reginald
See Remarks
- 576
8.8935 USD
1 year ago
Aug 02, 2023
Sell 31.1 K USD
Seeto Reginald
See Remarks
- 2733
11.372 USD
1 year ago
Aug 02, 2023
Sell 908 USD
Seeto Reginald
See Remarks
- 86
10.56 USD
1 year ago
Jul 13, 2023
Sell 54.4 K USD
Seeto Reginald
See Remarks
- 5260
10.3341 USD
1 year ago
Jul 13, 2023
Sell 51.7 K USD
Maag Peter
Director
- 5000
10.3361 USD
1 year ago
Jul 03, 2023
Sell 23.9 K USD
Seeto Reginald
See Remarks
- 2818
8.4815 USD
1 year ago
Jun 28, 2023
Sell 125 K USD
Seeto Reginald
See Remarks
- 14268
8.762 USD
1 year ago
Jun 28, 2023
Sell 21.2 K USD
Maag Peter
Director
- 2432
8.7235 USD
1 year ago
Jun 02, 2023
Sell 22.9 K USD
Seeto Reginald
See Remarks
- 2819
8.1275 USD
1 year ago
May 02, 2023
Sell 22.9 K USD
Seeto Reginald
See Remarks
- 2819
8.1227 USD
1 year ago
Apr 03, 2023
Sell 25.2 K USD
Seeto Reginald
See Remarks
- 2818
8.9514 USD
1 year ago
Mar 02, 2023
Sell 44.8 K USD
Seeto Reginald
See Remarks
- 2819
15.8772 USD
1 year ago
Feb 09, 2023
Sell 179 K USD
Seeto Reginald
See Remarks
- 11094
16.1284 USD
1 year ago
Feb 10, 2023
Sell 131 K USD
Seeto Reginald
See Remarks
- 8488
15.479 USD
1 year ago
Feb 07, 2023
Sell 50.3 K USD
Seeto Reginald
See Remarks
- 3069
16.4019 USD
1 year ago
Feb 08, 2023
Sell 51.5 K USD
Maag Peter
Director
- 3269
15.7543 USD
1 year ago
Feb 02, 2023
Sell 39.5 K USD
Seeto Reginald
See Remarks
- 2316
17.0733 USD
1 year ago
Feb 02, 2023
Sell 8.8 K USD
Seeto Reginald
See Remarks
- 503
17.5047 USD
1 year ago
Feb 02, 2023
Sell 85.8 K USD
Maag Peter
Director
- 5000
17.1659 USD
1 year ago
Jan 03, 2023
Sell 32.9 K USD
Seeto Reginald
See Remarks
- 2818
11.6877 USD
2 years ago
Aug 10, 2022
Sell 62.5 K USD
Colon Grace
director:
- 2521
24.81 USD
2 years ago
Aug 11, 2022
Sell 376 K USD
Maag Peter
director:
- 15415
24.3847 USD
2 years ago
Aug 11, 2022
Sell 117 K USD
Maag Peter
Director
- 4585
25.5732 USD
2 years ago
May 11, 2022
Sell 119 K USD
Colon Grace
director:
- 5179
23.01 USD
2 years ago
Apr 11, 2022
Sell 18 K USD
Goldberg Michael
director:
- 500
36.0128 USD
2 years ago
Apr 05, 2022
Sell 307 K USD
Maag Peter
Director
- 7982
38.4587 USD
2 years ago
Apr 05, 2022
Sell 79.4 K USD
Maag Peter
director:
- 2018
39.3543 USD
2 years ago
Mar 21, 2022
Sell 117 K USD
Seeto Reginald
See Remarks
- 2888
40.4343 USD
2 years ago
Mar 09, 2022
Sell 16.7 K USD
Goldberg Michael
director:
- 500
33.408 USD
2 years ago
Mar 09, 2022
Sell 48.1 K USD
Colon Grace
director:
- 1393
34.5629 USD
2 years ago
Mar 07, 2022
Sell 277 K USD
Maag Peter
director:
- 8500
32.6395 USD
2 years ago
Mar 07, 2022
Sell 50.6 K USD
Maag Peter
Director
- 1500
33.7512 USD
2 years ago
Mar 01, 2022
Sell 122 K USD
Seeto Reginald
See Remarks
- 3153
38.6152 USD
2 years ago
Feb 28, 2022
Sell 978 K USD
Bickerstaff George
Director
- 25000
39.1069 USD
2 years ago
Feb 09, 2022
Sell 115 K USD
Seeto Reginald
See Remarks
- 2550
45.0035 USD
2 years ago
Feb 09, 2022
Sell 21.5 K USD
Goldberg Michael
Director
- 500
42.96 USD
2 years ago
Feb 07, 2022
Sell 205 K USD
Maag Peter
Director
- 4900
41.8002 USD
2 years ago
Feb 07, 2022
Sell 216 K USD
Maag Peter
Director
- 5100
42.323 USD
2 years ago
Feb 04, 2022
Sell 201 K USD
Seeto Reginald
See Remarks
- 4988
40.3443 USD
2 years ago
Feb 02, 2022
Sell 131 K USD
Seeto Reginald
See Remarks
- 3182
41.25 USD
2 years ago
Feb 01, 2022
Sell 34.3 K USD
Seeto Reginald
See Remarks
- 814
42.13 USD
2 years ago
Jan 18, 2022
Sell 68.9 K USD
Seeto Reginald
See Remarks
- 1719
40.0703 USD
2 years ago
Jan 19, 2022
Sell 126 K USD
Seeto Reginald
See Remarks
- 3137
40.049 USD
2 years ago
Jan 10, 2022
Sell 21.5 K USD
Goldberg Michael
Director
- 500
42.97 USD
2 years ago
Jan 05, 2022
Sell 361 K USD
Maag Peter
Director
- 8146
44.2903 USD
2 years ago
Jan 05, 2022
Sell 83.7 K USD
Maag Peter
Director
- 1854
45.1331 USD
2 years ago
Dec 09, 2021
Sell 22.7 K USD
Goldberg Michael
Director
- 500
45.4105 USD
2 years ago
Dec 06, 2021
Sell 272 K USD
Maag Peter
Director
- 6588
41.2979 USD
2 years ago
Dec 06, 2021
Sell 131 K USD
Maag Peter
Director
- 3112
42.2035 USD
2 years ago
Dec 06, 2021
Sell 12.8 K USD
Maag Peter
Director
- 300
42.6067 USD
2 years ago
Nov 24, 2021
Bought 212 K USD
Dhingra Ankur
Chief Financial Officer
+ 5000
42.3387 USD
3 years ago
Nov 09, 2021
Sell 23.8 K USD
Goldberg Michael
Director
- 500
47.54 USD
3 years ago
Nov 05, 2021
Sell 494 K USD
Maag Peter
Director
- 10000
49.4 USD
3 years ago
Nov 05, 2021
Bought 28.6 K USD
TORRES ARTHUR A
Director
+ 600
47.62 USD
3 years ago
Oct 11, 2021
Sell 31.3 K USD
Goldberg Michael
Director
- 500
62.502 USD
3 years ago
Oct 05, 2021
Sell 336 K USD
Maag Peter
Executive Chair
- 5225
64.211 USD
3 years ago
Oct 05, 2021
Sell 235 K USD
Maag Peter
Executive Chair
- 3612
64.9467 USD
3 years ago
Oct 05, 2021
Sell 76.6 K USD
Maag Peter
Executive Chair
- 1163
65.9026 USD
3 years ago
Sep 07, 2021
Sell 647 K USD
Maag Peter
Executive Chair
- 8800
73.5545 USD
3 years ago
Sep 07, 2021
Sell 66.9 K USD
Maag Peter
Executive Chair
- 900
74.3211 USD
3 years ago
Sep 07, 2021
Sell 22.6 K USD
Maag Peter
Executive Chair
- 300
75.3133 USD
3 years ago
Aug 27, 2021
Sell 52.6 K USD
Seeto Reginald
See Remarks
- 658
80.003 USD
3 years ago
Jun 28, 2021
Sell 813 K USD
Seeto Reginald
See Remarks
- 8522
95.4177 USD
3 years ago
Jun 28, 2021
Sell 452 K USD
Seeto Reginald
See Remarks
- 4690
96.3413 USD
3 years ago
Jun 25, 2021
Sell 876 K USD
Seeto Reginald
See Remarks
- 9210
95.1485 USD
3 years ago
Aug 05, 2021
Sell 256 K USD
Maag Peter
Executive Chair
- 3096
82.8144 USD
3 years ago
Aug 05, 2021
Sell 575 K USD
Maag Peter
Executive Chair
- 6904
83.2734 USD
3 years ago
Jul 08, 2021
Sell 160 K USD
Seeto Reginald
See Remarks
- 1880
84.8746 USD
3 years ago
Jul 08, 2021
Sell 233 K USD
Seeto Reginald
See Remarks
- 2714
85.7367 USD
3 years ago
Jul 08, 2021
Sell 121 K USD
Seeto Reginald
See Remarks
- 1400
86.6069 USD
3 years ago
Jul 06, 2021
Sell 188 K USD
Maag Peter
Executive Chair
- 2100
89.4805 USD
3 years ago
Jul 06, 2021
Sell 217 K USD
Maag Peter
Executive Chair
- 2400
90.5456 USD
3 years ago
Jul 06, 2021
Sell 502 K USD
Maag Peter
Executive Chair
- 5500
91.2334 USD
3 years ago
Jun 24, 2021
Sell 915 K USD
Maag Peter
Executive Chair
- 9605
95.3043 USD
3 years ago
Jun 25, 2021
Sell 37.5 K USD
Maag Peter
Executive Chair
- 395
95 USD
3 years ago
Jun 24, 2021
Sell 1.01 M USD
Seeto Reginald
See Remarks
- 10602
95.3135 USD
3 years ago
Jun 09, 2021
Sell 227 K USD
Maag Peter
Executive Chair
- 2522
90.0006 USD
3 years ago
Jun 09, 2021
Sell 441 K USD
HAGSTROM WILLIAM A
Director
- 5000
88.1412 USD
3 years ago
Jun 09, 2021
Sell 1.12 M USD
King Sasha
Chief Marketing Officer
- 12435
90.0091 USD
3 years ago
Jun 09, 2021
Sell 1.5 M USD
Seeto Reginald
See Remarks
- 16718
90.0119 USD
3 years ago
May 27, 2021
Sell 159 K USD
SNYDERMAN RALPH
Director
- 1966
81.01 USD
3 years ago
May 28, 2021
Sell 204 K USD
SNYDERMAN RALPH
Director
- 2511
81.0811 USD
3 years ago
Jun 01, 2021
Sell 194 K USD
SNYDERMAN RALPH
Director
- 2512
77.2983 USD
3 years ago
Jun 02, 2021
Sell 205 K USD
SNYDERMAN RALPH
Director
- 2511
81.5672 USD
3 years ago
Jun 08, 2021
Sell 45 K USD
Seeto Reginald
See Remarks
- 500
90.002 USD
3 years ago
Jun 08, 2021
Sell 90 K USD
King Sasha
Chief Marketing Officer
- 1000
90.024 USD
3 years ago
Jun 08, 2021
Sell 88.1 K USD
Maag Peter
Executive Chair
- 978
90.0549 USD
3 years ago
Jun 07, 2021
Sell 1.7 M USD
Maag Peter
Executive Chair
- 20000
85.0341 USD
3 years ago
Jun 07, 2021
Sell 585 K USD
Maag Peter
Executive Chair
- 6500
90.0108 USD
3 years ago
Jun 07, 2021
Sell 898 K USD
Seeto Reginald
See Remarks
- 9973
90.0074 USD
3 years ago
Jun 07, 2021
Sell 726 K USD
King Sasha
Chief Marketing Officer
- 8071
90.0088 USD
3 years ago
May 25, 2021
Sell 773 K USD
Maag Peter
Executive Chair
- 9600
80.5667 USD
3 years ago
May 25, 2021
Sell 32.4 K USD
Maag Peter
Executive Chair
- 400
81.0763 USD
3 years ago
May 21, 2021
Sell 693 K USD
Bickerstaff George
Director
- 9201
75.2824 USD
3 years ago
May 21, 2021
Sell 60.7 K USD
Bickerstaff George
Director
- 799
75.9701 USD
3 years ago
May 14, 2021
Sell 574 K USD
HAGSTROM WILLIAM A
Director
- 8588
66.8221 USD
3 years ago
May 14, 2021
Sell 95 K USD
HAGSTROM WILLIAM A
Director
- 1412
67.2917 USD
3 years ago
May 12, 2021
Sell 592 K USD
Bickerstaff George
Director
- 9400
63.0318 USD
3 years ago
May 12, 2021
Sell 38.2 K USD
Bickerstaff George
Director
- 600
63.7467 USD
3 years ago
May 11, 2021
Sell 1.11 M USD
Goldberg Michael
Director
- 16793
65.8276 USD
3 years ago
May 11, 2021
Sell 1.08 M USD
Goldberg Michael
Director
- 16308
66.3462 USD
3 years ago
May 10, 2021
Sell 403 K USD
Goldberg Michael
Director
- 6042
66.7821 USD
3 years ago
May 10, 2021
Sell 12.6 K USD
Goldberg Michael
Director
- 183
68.6162 USD
3 years ago
May 11, 2021
Sell 836 K USD
Goldberg Michael
Director
- 12392
67.4925 USD
3 years ago
May 10, 2021
Sell 649 K USD
Goldberg Michael
Director
- 9217
70.3599 USD
3 years ago
May 11, 2021
Sell 245 K USD
Goldberg Michael
Director
- 3590
68.2975 USD
3 years ago
May 11, 2021
Sell 1.96 M USD
Maag Peter
Executive Chair
- 29792
65.8275 USD
3 years ago
May 11, 2021
Sell 1.92 M USD
Maag Peter
Executive Chair
- 28986
66.3466 USD
3 years ago
May 10, 2021
Sell 687 K USD
Maag Peter
Executive Chair
- 10284
66.782 USD
3 years ago
May 10, 2021
Sell 21.7 K USD
Maag Peter
Executive Chair
- 317
68.6111 USD
3 years ago
May 11, 2021
Sell 1.48 M USD
Maag Peter
Executive Chair
- 21985
67.4927 USD
3 years ago
May 10, 2021
Sell 1.1 M USD
Maag Peter
Executive Chair
- 15692
70.3599 USD
3 years ago
May 11, 2021
Sell 435 K USD
Maag Peter
Executive Chair
- 6365
68.298 USD
3 years ago
May 05, 2021
Sell 306 K USD
Maag Peter
Executive Chair
- 4210
72.6084 USD
3 years ago
May 05, 2021
Sell 259 K USD
Maag Peter
Executive Chair
- 3528
73.5325 USD
3 years ago
May 05, 2021
Sell 168 K USD
Maag Peter
Executive Chair
- 2262
74.3094 USD
3 years ago
May 03, 2021
Sell 1.3 M USD
Maag Peter
Executive Chair
- 16952
76.4959 USD
3 years ago
May 03, 2021
Sell 236 K USD
Maag Peter
Executive Chair
- 3048
77.4161 USD
3 years ago
May 03, 2021
Sell 1.3 M USD
Maag Peter
Executive Chair
- 16952
76.4959 USD
3 years ago
May 03, 2021
Sell 236 K USD
Maag Peter
Executive Chair
- 3048
77.4161 USD
3 years ago
Apr 05, 2021
Sell 107 K USD
Maag Peter
Executive Chair
- 1500
71.1463 USD
3 years ago
Apr 05, 2021
Sell 340 K USD
Maag Peter
Executive Chair
- 4700
72.4006 USD
3 years ago
Apr 05, 2021
Sell 277 K USD
Maag Peter
Executive Chair
- 3800
72.8982 USD
3 years ago
Mar 05, 2021
Sell 69.1 K USD
Maag Peter
Executive Chair
- 1200
57.5996 USD
3 years ago
Mar 05, 2021
Sell 47 K USD
Maag Peter
Executive Chair
- 800
58.7088 USD
3 years ago
Mar 05, 2021
Sell 98.7 K USD
Maag Peter
Executive Chair
- 1644
60.0254 USD
3 years ago
Mar 05, 2021
Sell 113 K USD
Maag Peter
Executive Chair
- 1856
61.0672 USD
3 years ago
Mar 05, 2021
Sell 112 K USD
Maag Peter
Executive Chair
- 1800
62.1325 USD
3 years ago
Mar 05, 2021
Sell 82.2 K USD
Maag Peter
Executive Chair
- 1300
63.2538 USD
3 years ago
Mar 05, 2021
Sell 57.7 K USD
Maag Peter
Executive Chair
- 900
64.1511 USD
3 years ago
Mar 05, 2021
Sell 13 K USD
Maag Peter
Executive Chair
- 200
65.183 USD
3 years ago
Mar 05, 2021
Sell 19.9 K USD
Maag Peter
Executive Chair
- 300
66.3383 USD
3 years ago
Mar 01, 2021
Sell 24.7 K USD
Seeto Reginald
See Remarks
- 300
82.3517 USD
3 years ago
Mar 01, 2021
Sell 50 K USD
Seeto Reginald
See Remarks
- 600
83.3213 USD
3 years ago
Mar 01, 2021
Sell 101 K USD
Seeto Reginald
See Remarks
- 1200
84.551 USD
3 years ago
Mar 01, 2021
Sell 557 K USD
Seeto Reginald
See Remarks
- 6504
85.6397 USD
3 years ago
Mar 01, 2021
Sell 182 K USD
Seeto Reginald
See Remarks
- 2100
86.4478 USD
3 years ago
Feb 05, 2021
Sell 715 K USD
Maag Peter
Executive Chair
- 7983
89.5759 USD
3 years ago
Feb 05, 2021
Sell 119 K USD
Maag Peter
Executive Chair
- 1316
90.3603 USD
3 years ago
Feb 05, 2021
Sell 60.1 K USD
Maag Peter
Executive Chair
- 657
91.533 USD
3 years ago
Feb 05, 2021
Sell 4.05 K USD
Maag Peter
Executive Chair
- 44
92.15 USD
7. News
Are Medical Stocks Lagging CareDx (CDNA) This Year? Here is how CareDx (CDNA) and Doximity (DOCS) have performed compared to their sector so far this year. zacks.com - 2 days ago
CareDx to Participate in Upcoming Investor Conferences BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in the following investor conferences. Jefferies London Healthcare Conference 2024 in London, UK. Presentation on Tuesday, November 19 at 9:00 AM GMT/4:00 AM EST. businesswire.com - 4 days ago
CareDx, Inc (CDNA) Q3 2024 Earnings Call Transcript CareDx, Inc (NASDAQ:CDNA ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Greg Chodaczek - Managing Director John Hanna - President and Chief Executive Officer Abhishek Jain - Chief Financial Officer Conference Call Participants Bill Bonello - Craig-Hallum Mark Massaro - BTIG Brandon Couillard - Wells Fargo Yi Chen - H.C. Wainwright Mason Carrico - Stephens Inc Thomas DeBourcy - Nephron Research Operator Good day, everyone, and welcome to today's CareDx, Inc. Third Quarter 2024 Earnings Conference Call. seekingalpha.com - 1 week ago
CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA NEW ORLEANS, LA / ACCESSWIRE / October 25, 2024 / Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq. accesswire.com - 3 weeks ago
CareDx, JD.com And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 10 points on Tuesday. benzinga.com - 1 month ago
CareDx Reports Preliminary Financial Results for Third Quarter 2024 BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers —today reported preliminary financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Third quarter revenue is expected to be in the range of $82 million to $83 million, a. businesswire.com - 1 month ago
CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA NEW ORLEANS , Oct. 11, 2024 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq. prnewswire.com - 1 month ago
CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on October 8, 2024, CareDx granted to Jing Huang, the Company's newly appointed Chief Data and AI Officer, 15,547 restricted stock units (“RSUs”) and an option to purchase 22,248 shares. businesswire.com - 1 month ago
CareDx Appoints Jing Huang Chief Data and AI Officer BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the appointment of Jing Huang Ph.D., in the newly created role of Chief Data and Artificial Intelligence (AI) Officer. Huang will lead key data science initiatives that are a part of the Compa. businesswire.com - 1 month ago
CareDx to Host Investor Day on October 15, 2024 BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the Company will be hosting an Investor Day on October 15, 2024, in New York City, New York, starting at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time. The event will feature presentations. businesswire.com - 1 month ago
CareDx Announces Closure of DOJ Investigation with No Finding of Wrongdoing BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Department of Justice (DOJ) has concluded its investigation into CareDx with no finding of wrongdoing and declined to take any further action. In a Court document unsealed on October. businesswire.com - 1 month ago
CareDx Inc (CDNA) Trading 6.16% Higher on Oct 2 Shares of CareDx Inc (CDNA, Financial) surged 6.16% in mid-day trading on Oct 2. The stock reached an intraday high of $32.97, before settling at $32.83, up from its previous close of $30.93. gurufocus.com - 1 month ago
8. Profile Summary

CareDx, Inc CDNA

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 1.14 B
Dividend Yield 0.00%
Description CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Contact 1 Tower Place, South San Francisco, CA, 94080 https://www.caredx.com
IPO Date July 17, 2014
Employees 635
Officers Mr. Abhishek Jain Chief Financial Officer & Principal Accounting Officer Mr. Kashif Rathore Head of Software Engineering Mr. Jeffrey A. Novack General Counsel & Secretary Mr. Keith S. Kennedy C.F.A., CPA Chief Operating Officer Ms. Jessica Meng Chief Commercial Officer Dr. Robert N. Woodward Ph.D. Chief Scientific Officer Ms. Marica Grskovic Ph.D. Chief Strategy Officer Ms. Stacey Follon Senior Vice President & Head of Human Resources Dr. Peter Maag Ph.D. Executive Director Mr. John Walter Hanna Jr. President, Chief Executive Officer & Director